Declaration of interests JBB has received salary support from clinical trial contracts to his employer by Corcept Therapeutics, Dexcom, GentiBio, Novo Nordisk, and Sparrow Pharmaceuticals; has received salary support from consulting contracts to his employer by Novo Nordisk; is a consultant with personal compensation from Aardvark Therapeutics, Altimmune, Alveus Therapeutics, Amgen, Antag Therapeutics, Aqua Medical, AstraZeneca, Boehringer Ingelheim, Corcept Therapeutics, Dexcom, Eli Lilly, Embecta, General Medicines, GentiBio, Kayothera, Metsera, MiniMed, Pfizer, Recordati, Roche, Sparrow Pharmaceuticals, Vertex, vTv Therapeutics, and Zealand Pharma; has stock options in Aardvark Therapeutics, Glyscend, Mellitus Health, Metsera, Pendulum Therapeutics, Praetego, and Stability Health; and has received salary support from grants from the National Institutes of Health, Breakthrough T1D, and the Patient-Centered Outcomes Research Institute. HSB has received funded grants or clinical trial payments made to his institution from Abbott, Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Ionis, Novartis, Novo Nordisk, Pfizer, Roche, and Vertex; and advisory or speakers funding from Eli Lilly, Novo Nordisk, Roche, and Sandoz. S-MD, LD, HHHD, and TWF are employees at Novo Nordisk. S-MD, LD, and HHHD are also shareholders of Novo Nordisk. MH received lecture or advisory board fees from AstraZeneca, Berlin Chemie, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Novo Nordisk, and Sanofi; and research support from Sanofi. IL received research funding (paid to institution) or product from Boehringer Ingelheim, Dexcom, Eli Lilly, Novo Nordisk, Pfizer, and Roche; research-related consulting fees (paid to institution) from Novo Nordisk; and advisory or consulting fees or other support from Aardvark Therapeutics, AbbVie, ADARx, Altasciences, Alveus Therapeutics, Amgen, Antag Therapeutics, Arrowhead Pharmaceuticals, AstraZeneca, Baim Institute, Bain Capital, Bayer, Betagenon, BIOIO, Biomea Fusion, Boehringer Ingelheim, Boston Scientific, Carmot Therapeutics, CORXEL, Cytoki Pharma, Eli Lilly, Genentech, Janssen/Johnson & Johnson, Juvena, Keros Therapeutics, Mediflix, Metsera, Neurocrine, Novo Nordisk, PENGUINBIO, Pfizer, Regeneron, Response Pharmaceuticals, Roche, Sanofi, Shionogi, Sparrow Pharmaceuticals, Skye Bioscience, Source Bio, Structure Therapeutics, SUMMIT, Tenvie, TERNS Pharma, Verdiva Bio, Viking Therapeutics, and Zealand Pharma. SDP received honoraria from Abbott, AbbVie, Amgen, AstraZeneca, Bausch, Boehringer Ingelheim, Dexcom, GSK, HLS Therapeutics, Janssen, Merck, Novo Nordisk, Pfizer, Roche, and Sanofi; research funding from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Pfizer, Prometic, and Sanofi; and speaker fees from Abbott, AstraZeneca, Bausch, Bayer, Boehringer Ingelheim, Dexcom, Eli Lilly, GSK, HLS Therapeutics, Janssen, Merck, Novo Nordisk, Regeneron, Roche, and Sanofi. REP received National Institutes of Health research grants U01DK106993, R01DK138060, U01DK35131, R01DK143524, U01DK143384, and U01DK127392; investigator-initiated grant support (directed to his institution) from Abbott Laboratories, AstraZeneca, Biomea Fusion, Boehringer Ingelheim International GmbH, Carmot Therapeutics, Dompé, Eli Lilly and Company, Endogenex, Fractyl, Lexicon, National Institutes of Health, Novo Nordisk, and Sanofi; consultancy fees from Abbott Laboratories, AbbVie, Altanine, Amgen, AstraZeneca Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Corcept Therapeutics, Crinetics Pharmaceuticals, Endogenex, F Hoffmann-La Roche, Hanmi Pharmaceutical, Novo Nordisk, Pfizer, Recordati Rare Diseases, Regeneron Pharmaceuticals, Response Pharmaceuticals, Rona Therapeutics, Scholar Rock, Sun Pharmaceutical Industries, Third Rock Ventures, and Verdiva Bio Dev; speaker fees from Lilly USA and Novo Nordisk; and stock options from Altanine. ABJ has received clinical trials funding from Abbott, Amgen, Argenx, AstraZeneca, Eli Lilly, Novo Nordisk, Roche, and Sanofi Aventis; and has received speaking honorarium or advisory compensation from Abbott, AbbVie, AstraZeneca, Amgen, Antibody, Bausch Healthcare, Bayer, Boehringer Ingelheim, Celltrion, Dexcom, Diabetes Canada, Eli Lilly, Embecta, GSK, HLS Therapeutics, Insulet, Janssen, Kailera, Merck, Medtronic, Moderna, Novartis, Novo Nordisk, Pendopharm, Pfizer, Roche, Sandoz, Takeda, and Ypsomed.
PubMed
